Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Current Deferred Revenue (2020 - 2025)

Ovid Therapeutics filings provide 2 years of Current Deferred Revenue readings, the most recent being $718000.0 for Q3 2025.

  • Quarterly Current Deferred Revenue changed N/A to $718000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $718000.0 through Sep 2025, changed N/A year-over-year, with the annual reading at $2.2 million for FY2020, N/A changed from the prior year.
  • Current Deferred Revenue hit $718000.0 in Q3 2025 for Ovid Therapeutics, roughly flat from $718000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $718000.0 in Q2 2025 and bottomed at $718000.0 in Q2 2025.